NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welch's
September 17 2007 - 9:45AM
PR Newswire (US)
HUBBARD, Ohio, Sept. 17 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(OTC:NNLX), a nano-biotechnology company, announced it has achieved
a historical event with the first onsite generation of electricity
using hydrogen gas produced from its bioreactor prototype facility
at Welch Foods Inc., a Cooperative in Pennsylvania. A 5.5 kW
generator converted to run on hydrogen was utilized for the
demonstration. The generator ran flawlessly on hydrogen gas
produced by NanoLogix's hydrogen bioreactor system and powered
multiple strings of 100- watt light bulbs. "To the best of our
knowledge, this is the first time in history that electricity has
been generated anywhere onsite using hydrogen produced through the
use of bacteria to digest waste", said Harry Diz, Department Chair
and Professor of Environmental Engineering at Gannon University and
NanoLogix Bioreactor Development chief. Paul Zorzie, Welch's
Engineering Manager, stated, "Welch's is happy to provide the site
at which this groundbreaking research into generating alternative
energy from waste is taking place. We look forward to the potential
of building upon these developments to scale up and use this energy
for our operation." Bret Barnhizer, Chairman and CEO of NanoLogix,
stated, "We are delighted at the results of the work by Professor
Diz and associates and anticipate potential upscaling of the
Welch's operation to commercial bioreactor status. The Welch's
development, enabling conversion of sugar from their wastewater
stream to produce hydrogen, has contributed immeasurably to ongoing
research and development for processing other types of waste
streams. Linked to that development and following our business plan
for expansion, in the spring of 2008 we intend to begin bioreactor
construction at the Erie Wastewater Treatment Plant for the
extraction of hydrogen from their protein-rich activated sludge
waste stream." About NanoLogix, Inc. NanoLogix is a leading
innovator in the research, development, and commercialization of
nano-biotechnologies, applications and processes. The Company has
31 granted Patents and 36 Patents Pending for bioreactor-based
hydrogen production, revolutionary rapid medical testing
technologies, potential treatments for sepsis and cancer, and
bioremediation. Information on NanoLogix is available at
http://www.nanologixinc.com/. This press release contains
statements, which may constitute "forward- looking statements"
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements
regarding the intent, belief or current expectations of NanoLogix,
Inc., and members of its management as well as the assumptions on
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Investor Relations Bret Barnhizer, CEO Telephone:
330-534-0800 E-mail: DATASOURCE: NanoLogix Inc. CONTACT: Investor
Relations, Bret Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800,
Web site: http://www.nanologixinc.com/
Copyright